Table 2.
Selected clinical trials registered at ClinTrials.gov on stem cell therapy for Alzheimer’s disease as of October, 2017.
| NCT number | Trial title | Interventions in experimental arm | Sponsor | Status |
|---|---|---|---|---|
| NCT02833792 | A Phase IIa Study of Allogeneic Human Mesenchymal Stem Cells in Subjects With Mild to Moderate Dementia Due to Alzheimer’s Disease | Human adult ischemia-tolerant mesenchymal stem cells and lactated Riunger’s solution via intravenous administration | Stemedica Cell Technologies, Inc., United States | Recruiting starts from June, 2016 |
| NCT02600130 | A Phase I, Prospective, Randomized, Double-Blinded, Placebo-controlled Trial to Evaluate the Safety and Potential Efficacy of Longeveron Allogeneic Human Mesenchymal Stem Cell (LMSCs) Infusion Versus Placebo in Patients With Alzheimer’s Disease | Longeveron mesenchymal stem cells (high-dose or low-dose) via peripheral intravenous infusion | Longeveron LLC, United States | Recruiting starts from August, 2016 |
| NCT02054208 | A Double-Blind, Single-Center, Phase 1/2a Clinical Trial to Evaluate the Safety and Exploratory Efficacy of Intraventricular Administrations of NEUROSTEM Versus Placebo Via an Ommaya Reservoir in Patients With Alzheimer’s Disease | NEUROSTEM® (human umbilical cord blood-derived mesenchymal stem cells) via intraventricular administrations | Medipost Co. Ltd., South Korea | Recruiting starts from February, 2014 |
| NCT01297218 | A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AstroStem, Autologous Adipose Tissue Derived Mesenchymal Stem Cells, in Patients With Alzheimer’s Disease | Autologous adipose tissue derived mesenchymal stem cells via intravenous injection | Nature Cell Co. Ltd., South Korea | Recruiting starts from April, 2017 |
| NCT02899091 | A Randomized, Double-Blind, Placebo-Controlled, Phase I/IIa Clinical Trial for Evaluation of Safety and Potential Therapeutic Effect After Transplantation of CB-AC-02 in Patients With Alzheimer’s Disease | CB-AC-02 (placenta-derived mesenchymal stem cells) via injection | CHABiotech CO., Ltd., South Korea | Not yet recruiting |
| NCT02912169 | An Open-label, Non-randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Vascular Fraction (AD-SVF) Cells Delivered Intravenous (IV) and Intranasal in Patients With Alzheimer’s Disease | Autologous Adipose-Derived Stromal Vascular Fraction (AD-SVF) Cells Delivered Intravenous (IV) and Intranasal | Ageless Regenerative Institute, United States | Recruiting starts from November, 2015 |
| NCT03297177 | Use of Autologous Stem Cell Use in Neurological Non-neoplastic Disorders and Disease | Autologous stem/stromal cells derived from subdermal fat deposit via intravenous parenteral route | Healeon Medical Inc., United States | Recruiting starts from December, 2017 |